Correction to “Nanobiotechnology‐mediated radioimmunotherapy treatment for triple‐negative breast cancer”. // MedComm - Biomaterials and Applications. – 2026. – DOI: 10.1002/mba2.70098. – URL: https://onlinelibrary.wiley.com/doi/10.1002/mba2.70098?af=R
(2026). Correction to “Nanobiotechnology‐mediated radioimmunotherapy treatment for triple‐negative breast cancer”. MedComm - Biomaterials and Applications. https://doi.org/10.1002/mba2.70098
“Correction to “Nanobiotechnology‐mediated radioimmunotherapy treatment for triple‐negative breast cancer”.” MedComm - Biomaterials and Applications, 2026. doi:10.1002/mba2.70098.
@article{article84458,
title = {Correction to “Nanobiotechnology‐mediated radioimmunotherapy treatment for triple‐negative breast cancer”},
journal = {MedComm - Biomaterials and Applications},
year = {2026},
doi = {10.1002/mba2.70098},
url = {https://onlinelibrary.wiley.com/doi/10.1002/mba2.70098?af=R}
}
Nature Biomedical Engineering, Published online: 18 November 2026; doi:10.1038/s41551-026-01843-z Tumour-associated mucins induce the disassembly of a designer PEGylated paclitaxel-conjugated nanomedicine into small unimers that escape...